vadimezan has been researched along with Malignant Mesothelioma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cornwall, SMJ; Graham, PT; Larma, I; Nelson, DJ; Nowak, AK | 1 |
1 other study(ies) available for vadimezan and Malignant Mesothelioma
| Article | Year |
|---|---|
The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model.
Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Disease Models, Animal; Mesothelioma; Mesothelioma, Malignant; Mice; Ovalbumin; T-Lymphocytes, Cytotoxic | 2022 |